Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GD2 CAR T Cells in Children and Young Adults With GD2+ Solid Tumors
NCT02107963Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Anti-GD2-CAR engineered T cells in osteosarcoma (OS), neuroblastoma, melanoma and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Feasibility of producing anti GD2-CAR cells at 29 days and Safety of administering escalating doses of anti-GD2-CAR engineered T cells. Started Feb 2014; status: completed.
02
Drugs
Anti-GD2-CAR engineered T cells
03
Conditions
osteosarcoma (OS)neuroblastomamelanomasarcoma
Beyond the preview
Go deeper on NCT02107963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107963.